May 13, 2020 / 9:57 PM / 11 days ago

BRIEF-G1 Therapeutics To Present Data Showing Myelopreservation Benefits Of Trilaciclib In Patients With Small Cell Lung Cancer

May 13 (Reuters) - G1 Therapeutics Inc:

* G1 THERAPEUTICS TO PRESENT DATA SHOWING MYELOPRESERVATION BENEFITS OF TRILACICLIB IN PATIENTS WITH SMALL CELL LUNG CANCER AT THE ASCO20 VIRTUAL SCIENTIFIC PROGRAM

* G1 THERAPEUTICS INC - NEW DRUG APPLICATION (NDA) SUBMISSION FOR TRILACICLIB IN SCLC ON TRACK FOR COMPLETION IN 2Q20

* G1 THERAPEUTICS - TRILACICLIB SIGNIFICANTLY REDUCED MYELOSUPPRESSION, NEED FOR RELATED SUPPORTIVE CARE INTERVENTIONS FOR PATIENTS WITH SMALL CELL LUNG CANCER Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below